◢ TECHNICA.BIOBIOTECH ECOSYSTEM INTELLIGENCE
Polish Biotech Scene

SensDx

Electrochemical biosensors · Rapid pathogen detection

Phase 3GPW NewConnectWarsaw
Focus / modality
Electrochemical biosensors
Lead asset
SensDx device
Type
Diagnostics
Indication
Rapid pathogen detection
Stage
Phase 3
HQ
Warsaw
Capital tier
GPW NewConnect
Backing
GPW NewConnect

Overview

Electrochemical biosensor platform for fast, point-of-care detection of viral and bacterial pathogens.

What they do

SensDx is a Polish biotech developing an electrochemical biosensor platform for fast, point-of-care detection of pathogens. The approach uses electrochemical sensing (reportedly with engineered biorecognition elements binding to viral or bacterial targets) on a reusable reader paired with disposable test components, aimed at delivering rapid results outside the central laboratory. The company is associated with Poland's Institute of Biotechnology and Molecular Medicine.

Lead program & status

The lead asset is the SensDx device and its accompanying pathogen-specific tests, positioned for respiratory and other infectious-disease targets (for example influenza and SARS-CoV-2 type indications). The general advantages claimed for electrochemical biosensing, fast response, high sensitivity and selectivity, low sample volume and miniaturization, underpin the product thesis. As of available public information, specific regulatory clearances (such as CE-IVD scope), independent clinical-validation data and current commercial status were not confirmed, so claims about deployed test menus should be treated cautiously.

Why it matters

Rapid, decentralized pathogen detection matters for outbreaks, clinics and pharmacies where lab turnaround is too slow. An electrochemical reader-plus-disposable model could offer molecular-like specificity at point of care, complementing antigen tests and lab PCR if validation and certification are achieved.

FAQ

What is the SensDx platform?
An electrochemical biosensor system, a reader paired with disposable test components, designed to detect viral and bacterial pathogens rapidly at the point of care rather than in a central lab.
What can it detect?
It is positioned for infectious-disease targets such as respiratory pathogens (for example influenza- and SARS-CoV-2-type indications); the exact validated test menu and certifications are not fully confirmed in public sources.
Why use electrochemical biosensors?
They can offer fast response, high sensitivity and selectivity, low sample volumes and easy miniaturization, which suits portable, point-of-care diagnostic devices.

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

No spam · ~1–2 emails/month · unsubscribe anytime.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.